Semaglutide tablets vs injection for weight loss: a side-by-side look

Step 1 — understand how each form enters your body

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that slows gastric emptying, reduces appetite, and helps regulate blood sugar. The mechanism is the same whether you inject it or swallow it, but the route of administration changes almost everything else about the experience.

The weekly injection delivers semaglutide directly into the tissue beneath the skin, where it is absorbed steadily over seven days. Absorption is consistent and predictable, which is why clinical trials could reliably measure outcomes across thousands of participants.

The tablet is co-formulated with SNAC, an absorption enhancer that briefly raises the local pH in the stomach lining, allowing a portion of the semaglutide to pass into the bloodstream. Because the gut is a harsh environment for peptide medicines, a higher tablet dose is needed to achieve a similar circulating level, hence the 25mg maintenance tablet compared with the 2.4mg weekly injection. You can read more about the tablet's specific requirements on the how to use semaglutide tablets for weight loss page, but the short version is: first thing in the morning, plain water only, nothing else for at least thirty minutes. A consistent daily habit matters more with the tablet than with the injection.

Neither form requires special medical training to use. The injection involves a small pre-filled pen; the tablet is swallowed whole. The practical difference is daily versus weekly.

Step 2, weigh the evidence on weight loss outcomes

The injection has the longer track record. In the STEP 1 trial (68 weeks, semaglutide 2.4mg versus placebo), participants lost an average of around 15% of body weight, published in the New England Journal of Medicine and the basis for NICE's recommendation of Wegovy (TA875). A higher 7.2mg dose was approved by the MHRA in early 2026, with trial data pointing to roughly 20.7% average weight loss over 72 weeks at that dose, which brings it closer to tirzepatide territory.

The tablet evidence comes from the OASIS 4 phase-3 trial (64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes). The average weight loss was around 13.6% against roughly 2.4% for placebo. Among participants who stayed fully adherent to the regimen throughout the trial, the figure rose to about 17%. That 17% number is real, but context matters: it reflects complete adherence, not an average you should plan around. The MHRA approved the tablet on 11 June 2026 based on this data.

The numbers favour the injection slightly overall, though the tablet's results are clinically meaningful. If you want to understand how these two formats compare side by side in more depth, our semaglutide tablets vs injection page walks through the key differences in detail, because adherence is where outcomes diverge in real life.

Step 3 (compare the practical trade-offs

Storage is a practical dividing line. The injection pen lives in the fridge, for most people that means the fridge door, alongside the usual clutter. The tablet sits at room temperature, which makes it considerably simpler to travel with or keep at a desk. If needles are a firm barrier rather than a mild preference, the tablet removes the issue entirely. If a strict morning routine sounds difficult to maintain, a weekly injection may suit you better.

Side effects share a GI profile across both forms: nausea, constipation, diarrhoea, and indigestion are the most common, usually most noticeable when starting or after a dose increase, and often settling within a couple of weeks. The NHS semaglutide medicines page covers these in full. In the OASIS 4 trial, 74% of tablet users reported gastrointestinal side effects versus 42% on placebo, a higher proportion than typically seen with the injection, though most were mild to moderate.

Step 4, what neither form is, and who makes the call

A note worth stating clearly: Ozempic and Rybelsus are also semaglutide products, but they are licensed for type 2 diabetes, not weight management. They are not interchangeable with Wegovy injection or Wegovy tablets for weight loss, and a prescriber would not issue them for that purpose. The semaglutide tablets overview page covers this distinction if you have seen references to other tablet strengths online.

Eligibility for either form requires a clinical assessment. The licensed criteria overlap (broadly, adults with a BMI of 30 or above, or 27 and above with a qualifying weight-related condition) but the tablet's approval was specifically for BMI 30 or above at the 25mg maintenance level, and lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. A prescriber checks the full picture: your medical history, current medicines, and goals.

Neither product is available on the NHS without specialist referral, and NICE's recommendation for the injection (TA875) requires use within a specialist weight management service for a maximum of two years. Private treatment through a regulated pharmacy is the route most people take when they want to start without a long wait. Our semaglutide oral vs injection page is a good place to explore how those two routes differ before you decide. Which form suits you is a clinical decision our prescribers make with you, not a verdict we can hand down from a comparison page. Speak to our prescribers to work through it.